Literature DB >> 33164933

Revised Framingham Stroke Risk Profile: Association with Cognitive Status and MRI-Derived Volumetric Measures.

Isabelle Pelcher1, Christian Puzo1, Yorghos Tripodis2, Hugo J Aparicio1,3,4,5, Eric G Steinberg1, Alyssa Phelps1, Brett Martin6, Joseph N Palmisano6, Elizabeth Vassey1, Cutter Lindbergh7, Ann C McKee1,3,4,8,9, Thor D Stein1,4,5,8,9, Ronald J Killiany1,10, Rhoda Au1,3,5,10,11, Neil W Kowall1,3,4, Robert A Stern1,3,10,12, Jesse Mez1,3, Michael L Alosco1,3.   

Abstract

BACKGROUND: The Framingham Stroke Risk Profile (FSRP) was created in 1991 to estimate 10-year risk of stroke. It was revised in 2017 (rFSRP) to reflect the modern data on vascular risk factors and stroke risk.
OBJECTIVE: This study examined the association between the rFSRP and cognitive and brain aging outcomes among participants from the National Alzheimer's Coordinating Center (NACC) Uniform Data Set (UDS).
METHODS: Cross-sectional rFSRP was computed at baseline for 19,309 participants (mean age = 72.84, SD = 8.48) from the NACC-UDS [9,697 (50.2%) normal cognition, 4,705 (24.4%) MCI, 4,907 (25.4%) dementia]. Multivariable linear, logistic, or ordinal regressions examined the association between the rFSRP and diagnostic status, neuropsychological test performance, CDR® Sum of Boxes, as well as total brain volume (TBV), hippocampal volume (HCV), and log-transformed white matter hyperintensities (WMH) for an MRI subset (n = 1,196). Models controlled for age, sex, education, racial identity, APOEɛ4 status, and estimated intracranial volume for MRI models.
RESULTS: The mean rFSRP probability was 10.42% (min = 0.50%, max = 95.71%). Higher rFSRP scores corresponded to greater CDR Sum of Boxes (β= 0.02, p = 0.028) and worse performance on: Trail Making Test A (β= 0.05, p < 0.001) and B (β= 0.057, p < 0.001), and Digit Symbol (β= -0.058, p < 0.001). Higher rFSRP scores were associated with increased odds for a greater volume of log-transformed WMH (OR = 1.02 per quartile, p = 0.015). No associations were observed for diagnosis, episodic memory or language test scores, HCV, or TBV.
CONCLUSION: These results support the rFSRP as a useful metric to facilitate clinical research on the associations between cerebrovascular disease and cognitive and brain aging.

Entities:  

Keywords:  Alzheimer’s disease; cardiovascular disease; cerebrovascular disease; framingham stroke risk profile; stroke risk

Year:  2020        PMID: 33164933      PMCID: PMC7887636          DOI: 10.3233/JAD-200803

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  85 in total

1.  The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

Authors:  Marilyn S Albert; Steven T DeKosky; Dennis Dickson; Bruno Dubois; Howard H Feldman; Nick C Fox; Anthony Gamst; David M Holtzman; William J Jagust; Ronald C Petersen; Peter J Snyder; Maria C Carrillo; Bill Thies; Creighton H Phelps
Journal:  Alzheimers Dement       Date:  2011-04-21       Impact factor: 21.566

Review 2.  Update on hypertension and Alzheimer's disease.

Authors:  Ingmar Skoog; Deborah Gustafson
Journal:  Neurol Res       Date:  2006-09       Impact factor: 2.448

Review 3.  Cardiovascular risk factors and dementia.

Authors:  Howard Fillit; David T Nash; Tatjana Rundek; Andrea Zuckerman
Journal:  Am J Geriatr Pharmacother       Date:  2008-06

4.  Modeling the Relationships Among Late-Life Body Mass Index, Cerebrovascular Disease, and Alzheimer's Disease Neuropathology in an Autopsy Sample of 1,421 Subjects from the National Alzheimer's Coordinating Center Data Set.

Authors:  Michael L Alosco; Jonathan Duskin; Lilah M Besser; Brett Martin; Christine E Chaisson; John Gunstad; Neil W Kowall; Ann C McKee; Robert A Stern; Yorghos Tripodis
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

5.  APOE genotype modifies the relationship between midlife vascular risk factors and later cognitive decline.

Authors:  Katherine J Bangen; Alexa Beiser; Lisa Delano-Wood; Daniel A Nation; Melissa Lamar; David J Libon; Mark W Bondi; Sudha Seshadri; Philip A Wolf; Rhoda Au
Journal:  J Stroke Cerebrovasc Dis       Date:  2013-04-17       Impact factor: 2.136

6.  The neuropsychological profile of vascular cognitive impairment in stroke and TIA patients.

Authors:  P S Sachdev; H Brodaty; M J Valenzuela; L Lorentz; J C L Looi; W Wen; A S Zagami
Journal:  Neurology       Date:  2004-03-23       Impact factor: 9.910

7.  White matter hyperintensities and subclinical infarction: associations with psychomotor speed and cognitive flexibility.

Authors:  Clinton B Wright; Joanne R Festa; Myunghee C Paik; Alexis Schmiedigen; Truman R Brown; Mitsuhiro Yoshita; Charles DeCarli; Ralph Sacco; Yaakov Stern
Journal:  Stroke       Date:  2008-02-07       Impact factor: 7.914

8.  Framingham Stroke Risk Profile is related to cerebral small vessel disease progression and lower cognitive performance in patients with hypertension.

Authors:  Renske Uiterwijk; Julie Staals; Marjolein Huijts; Peter W de Leeuw; Abraham A Kroon; Robert J van Oostenbrugge
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-01-22       Impact factor: 3.738

9.  Independent effects of white matter hyperintensities on cognitive, neuropsychiatric, and functional decline: a longitudinal investigation using the National Alzheimer's Coordinating Center Uniform Data Set.

Authors:  Christian Puzo; Caroline Labriola; Michael A Sugarman; Yorghos Tripodis; Brett Martin; Joseph N Palmisano; Eric G Steinberg; Thor D Stein; Neil W Kowall; Ann C McKee; Jesse Mez; Ronald J Killiany; Robert A Stern; Michael L Alosco
Journal:  Alzheimers Res Ther       Date:  2019-07-27       Impact factor: 6.982

10.  Associations between blood pressure across adulthood and late-life brain structure and pathology in the neuroscience substudy of the 1946 British birth cohort (Insight 46): an epidemiological study.

Authors:  Christopher A Lane; Josephine Barnes; Jennifer M Nicholas; Carole H Sudre; David M Cash; Thomas D Parker; Ian B Malone; Kirsty Lu; Sarah-Naomi James; Ashvini Keshavan; Heidi Murray-Smith; Andrew Wong; Sarah M Buchanan; Sarah E Keuss; Elizabeth Gordon; William Coath; Anna Barnes; John Dickson; Marc Modat; David Thomas; Sebastian J Crutch; Rebecca Hardy; Marcus Richards; Nick C Fox; Jonathan M Schott
Journal:  Lancet Neurol       Date:  2019-08-20       Impact factor: 44.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.